{"id":1848,"date":"2023-04-18T16:44:00","date_gmt":"2023-04-18T14:44:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1848"},"modified":"2024-08-01T14:13:52","modified_gmt":"2024-08-01T12:13:52","slug":"26c-liecivo-atezolizumab-tecentriq-na-liecbu-lokalne-pokrocileho-alebo-metastatickeho-nemalobunkoveho-karcinomu-pluc-po-predchadzajucej-chemoterapii","status":"publish","type":"post","link":"https:\/\/www.niho.sk\/en\/26c-liecivo-atezolizumab-tecentriq-na-liecbu-lokalne-pokrocileho-alebo-metastatickeho-nemalobunkoveho-karcinomu-pluc-po-predchadzajucej-chemoterapii\/","title":{"rendered":"26C: Lie\u010divo atezolizumab (Tecentriq) na lie\u010dbu lok\u00e1lne pokro\u010dil\u00e9ho alebo metastatick\u00e9ho nemalobunkov\u00e9ho karcin\u00f3mu p\u013e\u00fac po predch\u00e1dzaj\u00facej chemoterapii"},"content":{"rendered":"
    \n
  1. Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n

    Zhubn\u00fd n\u00e1dor p\u013e\u00fac je vo v\u00e4\u010d\u0161ine kraj\u00edn sveta naj\u010dastej\u0161ie diagnostikovanou malignitou u mu\u017eov a u \u017eien je celosvetovo na \u0161tvrtom mieste. Pr\u00ed\u010dinou v\u00e4\u010d\u0161iny pr\u00edpadov ochorenia je faj\u010denie. Zhubn\u00e9 n\u00e1dory p\u013e\u00fac boli v roku 2019 naj\u010dastej\u0161ou onkologickou pr\u00ed\u010dinou \u00famrtia mu\u017eov a druhou naj\u010dastej\u0161ou onkologickou pr\u00ed\u010dinou \u00famrtia \u017eien na Slovensku. Ochorenie je \u010dasto zachyten\u00e9 a\u017e v lok\u00e1lne pokro\u010dilom alebo metastatickom \u0161t\u00e1diu, ke\u010f u\u017e nie je vylie\u010dite\u013en\u00e9. Lie\u010dba sa preto zameriava na pred\u013a\u017eenie pre\u017e\u00edvania a zv\u00fd\u0161enie kvality \u017eivota pacientov. Pacienti uv\u00e1dzaj\u00fa, \u017ee ochorenie m\u00e1 dopad na ich psychick\u00e9 pre\u017e\u00edvanie, ako aj na vz\u0165ahy s bl\u00edzkymi.<\/p>\n\n\n\n

      \n
    1. O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n

      Tecentriq je liek proti rakovine, ktor\u00fd obsahuje lie\u010divo atezolizumab. Atezolizumab patr\u00ed do skupiny liekov naz\u00fdvanej monoklon\u00e1lne protil\u00e1tky. Monoklon\u00e1lna protil\u00e1tka je typ bielkoviny vytvorenej tak, aby rozpoznala a naviazala sa na \u0161pecifick\u00fd cie\u013e v tele. T\u00e1to protil\u00e1tka m\u00f4\u017ee pom\u00f4c\u0165 v\u00e1\u0161mu imunitn\u00e9mu syst\u00e9mu bojova\u0165 proti rakovine.<\/p>\n\n\n\n

      Tento liek bol pre predmetn\u00fa indik\u00e1ciu registrovan\u00fd v Eur\u00f3pskej \u00fanii 20.9.2017.<\/p>\n\n\n\n

        \n
      1. Ako sa na atezolizumab pozeraj\u00fa odborn\u00edci?\u00a0<\/strong><\/li>\n<\/ol>\n\n\n\n

        Klinick\u00fd odborn\u00edk by priv\u00edtal kategoriz\u00e1ciu Tecentriqu v indik\u00e1cii lok\u00e1lne pokro\u010dil\u00fd alebo metastatick\u00fd NSCLC po predch\u00e1dzaj\u00facej chemoterapii, ke\u010f\u017ee lie\u010dba imunoterapiou v uvedenej indik\u00e1cii nie je dostupn\u00e1. Preto ju pova\u017euje za ch\u00fdbaj\u00faci \u010dl\u00e1nok v kontinuite komplexnej lie\u010dby.<\/p>\n\n\n\n

          \n
        1. \u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n

          Dr\u017eite\u013e registr\u00e1cie (Roche Registration GmbH (DEU)) podal \u017eiados\u0165 o zaradenie lieku Tecentriq (lie\u010divo atezolizumab) do \u00fahrad z verejn\u00e9ho zdravotn\u00e9ho poistenia pri pou\u017eit\u00ed na lie\u010dbu lok\u00e1lne pokro\u010dil\u00e9ho alebo metastatick\u00e9ho nemalobunkov\u00e9ho karcin\u00f3mu p\u013e\u00fac po predch\u00e1dzaj\u00facej chemoterapii. <\/p>\n\n\n\n

          NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Tecentriq v predmetnej indik\u00e1ci\u00ed, pokia\u013e dr\u017eite\u013e uprav\u00ed po\u017eadovan\u00fa v\u00fd\u0161ku \u00fahrady tak, aby sp\u013a\u0148ala krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti. Z\u00e1rove\u0148, z d\u00f4vodu vysokej miery neistoty pri odhadovan\u00ed dlhodob\u00e9ho pr\u00ednosu odpor\u00fa\u010dame po\u017eadova\u0165 od DR dodato\u010dn\u00fa z\u013eavu. <\/p>\n\n\n\n

          NIHO z\u00e1rove\u0148 odpor\u00fa\u010da:<\/p>\n\n\n\n

            \n
          • \u00fapravu indika\u010dn\u00e9ho obmedzenia pod\u013ea n\u00e1vrhu NIHO.<\/li>\n\n\n\n
          • aby sa liek indikoval len pacientom, ktor\u00fdch v\u00fdkonnostn\u00fd stav dosahuje \u0161pecifick\u00e9 sk\u00f3re na ECOG \u0161k\u00e1le (Eastern Cooperative Oncology Group performance status).<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"

            NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Tecentriq v predmetnej indik\u00e1ci\u00ed, pokia\u013e dr\u017eite\u013e uprav\u00ed po\u017eadovan\u00fa v\u00fd\u0161ku \u00fahrady tak, aby sp\u013a\u0148ala krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti a…<\/p>","protected":false},"author":3,"featured_media":1844,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[89,88],"class_list":["post-1848","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-atezolizumab","tag-tecentriq"],"_links":{"self":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1848"}],"version-history":[{"count":0,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1848\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media\/1844"}],"wp:attachment":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}